Elsevier

Maturitas

Volume 78, Issue 3, July 2014, Pages 205-211
Maturitas

Effects of Glycine max (L.) Merr. soy isoflavone vaginal gel on epithelium morphology and estrogen receptor expression in postmenopausal women: A 12-week, randomized, double-blind, placebo-controlled trial

https://doi.org/10.1016/j.maturitas.2014.04.007Get rights and content

Abstract

Objective

Evaluate the effects of vaginal administration of isoflavones derived from Glycine max (L.) Merr. as a treatment option for vaginal atrophy, on the morphology and expression of estrogen receptors in vaginal epithelium of postmenopausal women.

Methods

The double-blind, randomized, placebo-controlled, clinical trial. Sixty women were treated for 12 weeks with isoflavone vaginal gel 4% (1 g/day) and a placebo gel. After 4 and 12 weeks, the vaginal atrophy symptoms were classified at none, mild, moderate and severe and the vaginal cytology were taken to determine the maturation value. Vaginal pH was measured at the beginning and end of therapy. Microbiopsies in vaginal fornix were performed before the treatment and after 12 weeks of treatment.

Results

Isoflavone vaginal gel was effective for relief of vaginal dryness and dyspareunia symptons and an increase in the intermediate and superficial cells was noted. The vaginal pH in the isoflavone group was 7.1 at baseline and 5.4 after 12 weeks, whereas in the placebo group there was no significant change. A significant increase in thickness after treatment was detected in the Isoflavone Group. The percentage of estrogen receptor positive cells in vaginal epithelium for the Isoflavone Group ranged from 58.5% at the beginning of treatment to 82.6% after 12 weeks. These results were superior to placebo gel.

Conclusion

Glycine max (L.) Merr. at 4% vaginal gel on a daily basis in postmenopausal women led to improvements in vaginal atrophy symptoms, maturation values, vaginal pH, morphology and expression of estrogen receptors in vaginal epithelium. Isoflavones proved good treatment options for relief of vulvovaginal atrophy.

Introduction

Vaginal atrophy (VA) is a common condition in postmenopausal women associated with vaginal and/or urinary symptoms such as vaginal dryness, itching, discomfort and dyspareunia, dysuria, urinary urgency and frequency [1]. The disorder typically occurs in postmenopausal women, but can affect women of any age who experience a decrease in estrogenic stimulation of the urogenital tissues [2]. Sexual function and quality of life may also be reduced as a result of these changes [3].

According to The North American Menopause Society (NAMS), symptoms associated with vulvovaginal atrophy (VVA) affect 20–45% of midlife and older women, but this aspect of menopause is often overlooked and undermanaged, because only a minority seek medical help for the problem [4]. In contrast to vasomotor symptoms, which tend to improve over time even without treatment, VVA can be progressive and is less likely to resolve without intervention [4].

The primary goal of treating symptomatic VVA is to alleviate symptoms. First-line therapies include nonhormonal, long-acting vaginal moisturizers and low-dose vaginal estrogen, assuming no contraindications [4]. Despite the effectiveness of estrogen, concerns over side effects and safety have hindered its use by postmenopausal women. In recent years, phytoestrogen supplements have become attractive as safer alternatives, and their efficacy has been investigated in experimental and clinical trials [5], [6], [7], [8].

Isoflavones are the most studied of the phytoestrogens and some trials involving its oral form for treating climacteric symptomatology have shown no change in vaginal epithelium or endometrium [9], [10]. Similarly, topical preparations for the prevention and delay of skin maturation in postmenopausal women have shown satisfactory outcomes [11], [12].

Cytologic examination of vaginal mucosa from menopausal women shows a decreased proportion of superficial cells and an increased proportion of parabasal cells [13]. Also, the vaginal lining thins and vaginal pH increases from the normal 3.5–4.0 (which favors lactobacilli) to 6.0–8.0 (which favors pathogenic organisms) [14], [15].

Although cytohormonal analysis of the vaginal epithelium is well established as a method of evaluating oestrogenic influence, where maturation value (MV) can be calculated to express degree of vaginal atrophy as a numeric rating [16], in cytology analysis, only the exfoliated cells are studied. In order to gain a broader picture of the process of maturation of the vaginal epithelium a morphometric method should also be used.

Estrogen is a dominant regulator of vaginal physiology. Estrogen-receptor (ER) is present in the vaginal tissues of both premenopausal and postmenopausal women [17], [18]. The biological effect of estrogens is mediated by direct interaction with two ERs, ERα and ERβ. The ERs belong to the superfamily of steroid nuclear receptor transcription factors that activate binding to specific DNA sequences, called estrogen-responsive elements, on the promoters of the target genes [19].

Few studies investigating the effects of vaginal administration of isoflavones on vaginal atrophy symptoms are available [7], [20], [21] while no studies using the morphometric method as a means of assessing vaginal epithelium and ER expression in vaginal cells in postmenopausal women have been reported. The aim of the current investigation was to evaluate the effects of vaginal administration of isoflavones derived from Glycine max (L.) Merr. as a treatment option for vaginal atrophy, on the morphology and expression of estrogen receptors in vaginal epithelium of postmenopausal women.

Section snippets

Setting

The study commenced in July 2011 and was concluded in April 2013. The clinical trial was performed in accordance with the Declaration of Helsinki and International Standards of Good Clinical Practice (ICH-E6). The study protocol and patient informed consent form were approved by the Research Ethics Committee of the Irmandade da Santa Casa de Misericórdia de São Paulo hospital, in São Paulo – Brazil. All investigations were performed at this institution.

Study design

The double-blind, randomized,

Results

Of the 117 participants enrolled, 60 subjects remained after applying the inclusion and exclusion criteria. A total of 30 women received 1 gram of isoflavone vaginal gel 4% daily for 12 weeks and 30 women received 1 gram of placebo vaginal gel for the same period. In the placebo group, two women discontinued treatment due to lack of improvement and two subjects were lost to follow up. In the isoflavone group, one woman discontinued due to leucorrhea (Fig. 1). Patient baseline characteristics

Discussion

The effect of isoflavones derived from Glycine max (L.) Merr. in the treatment of vaginal atrophy by topical gel compared to placebo was evaluated. Systemic hormone therapy with natural estrogens is used for the relief of menopausal symptoms. However, a substantial proportion of women with urogenital complaints and changes in sexuality have no clinical improvement from systemic hormone treatment, where the combination of local treatment for relief of symptoms is required in this group [29].

Contributors

They were responsible for the clinical history, physical examination and treatment of the study participants, and also contributed to the writing of the paper, statistical tests and conclusions

Maria Antonieta L. Galvão da Silva (PhD) contributed to the cytological, morphological and immunohistochemical study.

Competing interests

None of the authors involved in this study have any form of conflict of interest.

Funding information

Funding for the entire study was conducted by researchers.

References (44)

  • C. Kaari et al.

    Randomized clinical trial comparing conjugated equine estrogens and isoflavones in postmenopausal women: a pilot study

    Maturitas

    (2006)
  • J. Manonai et al.

    The effect of a soy-rich diet on urogenital atrophy: a randomized, cross-over trial

    Maturitas

    (2006)
  • K. Nilsson et al.

    The vaginal epithelium in the postmenopause – cytology, histology and pH as methods of assessment

    Maturitas

    (1995)
  • North American Menopause Society

    The 2012 Hormone Therapy Position Statement of The North American Menopause Society

    Menopause

    (2012)
  • D.F. Archer

    Efficacy and tolerability of local estrogen therapy for urogenital atrophy

    Menopause

    (2010)
  • North American Menopause Society

    Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society

    Menopause

    (2013)
  • F.E. Drapier et al.

    Effects of a standardized soy extract on hot flushes: a multicenter, double blind, randomized, placebo controlled study

    Menopause

    (2002)
  • D.L. Alves et al.

    Effects of Tripholium pratense and Cimifuga racemosa on the endometrium of wistar rats

    Maturitas

    (2008)
  • D.H. Upmalis et al.

    Vasomotor symptom relief by soy isoflavone extract tablets in post-menopausal women: a multi-center, randomized, placebo-controled study

    Menopause

    (2000)
  • R. D’Anna et al.

    Effects of the phytoestrogen genistein on hot flushes, endometrium and vaginal epithelium in postmenopausal women: a 2-year randomized, double-blind, placebo-controlled study

    Menopause

    (2009)
  • M.T. Patriarca et al.

    Hyaluronic acid concentration in postmenopausal facial skin after topical estradiol and genistein treatment: a double-blind, randomized clinical trial of efficacy

    Menopause

    (2013)
  • G.A. Bachmann et al.

    Diagnosis and treatment of atrophic vaginitis

    Am Fam Phys

    (2000)
  • Cited by (39)

    • Estrogens and phytoestrogens in body functions

      2022, Neuroscience and Biobehavioral Reviews
      Citation Excerpt :

      The European Food Safety Authority (EFSA), with the nutrition and allergies (NDA) Panel 2018–2024, concluded that the available evidence is insufficient to establish a relationship between maintenance of bone mineral density and the consumption of soy isoflavones. In the treatment of climacteric symptoms, such as vaginal dryness, phytoestrogens administered orally did not induce changes in the vaginal epithelium, while treatment with topical preparations showed satisfactory results (Rosa Lima et al., 2014). The increase in cardiovascular risk and mortality in menopausal women, with respect to the previous reproductive period, provides a basis for the proposed role of estrogens and phytoestrogens in the reduction of cardiovascular disease (Rossouw et al., 2007; Sekikawa et al., 2019).

    • Impact of phytoestrogens on treatment of urogenital menopause symptoms: A systematic review of randomized clinical trials

      2021, European Journal of Obstetrics and Gynecology and Reproductive Biology
      Citation Excerpt :

      Systemic hormone therapy with natural estrogens issued for the relief of menopausal symptoms. However, a substantial proportion of women with urogenital complaints and changes in sexuality have no clinical improvement from systemic hormone treatment, where the combination of local treatment for relief of symptoms is required in this group [25,66]. Tedeschi and Benvenuti(2012) in a study compared symptoms of vaginal atrophy in women who received oral vaginal gel in addition to oral isoflavone and women who did not use any vaginal treatment.

    View all citing articles on Scopus
    View full text